Density scaling of phantom materials for a 3D dose verification system

Kensuke Tani1 | Yukio Fujita2 | Akihisa Wakita3 | Ryohei Miyasaka4 | Ryuzo Uehara5 | Takumi Kodama6 | Yuya Suzuki7 | Ako Aikawa3 | Norifumi Mizuno8 | Jiro Kawamori8 | Hidetoshi Saitoh1

1Department of Radiological Sciences, Graduate School of Tokyo Metropolitan University, Arakawa, Japan
2Department of Radiation Oncology, Tokai University School of Medicine, Isehara, Japan
3Department of Radiation Oncology, National Cancer Center Hospital, Tsukiji, Japan
4Department of Radiation Oncology, Chiba Cancer Center, Chiba, Japan
5Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Japan
6Department of Radiation Oncology, Saitama Cancer Center, Iri, Japan
7Department of Radiation Oncology, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Japan
8Department of Radiation Oncology, St. Luke’s International Hospital, Tokyo, Japan

Abstract

In this study, the optimum density scaling factors of phantom materials for a commercially available three-dimensional (3D) dose verification system (Delta4) were investigated in order to improve the accuracy of the calculated dose distributions in the phantom materials. At field sizes of 10 x 10 and 5 x 5 cm² with the same geometry, tissue-phantom ratios (TPRs) in water, polymethyl methacrylate (PMMA), and Plastic Water Diagnostic Therapy (PWDT) were measured, and TPRs in various density scaling factors of water were calculated by Monte Carlo simulation, Adaptive Convolve (AdC, Pinnacle3), Collapsed Cone Convolution (CCC, RayStation), and AcurosXB (AXB, Eclipse). Effective linear attenuation coefficients (l_eff) were obtained from the TPRs. The ratios of l_eff in phantom and water ((l_eff)_water) were compared between the measurements and calculations. For each phantom material, the density scaling factor proposed in this study (DSF) was set to be the value providing a match between the calculated and measured (l_eff)_water. The optimum density scaling factor was verified through the comparison of the dose distributions measured by Delta4 and calculated with three different density scaling factors: the nominal physical density (PD), nominal relative electron density (ED), and DSF. Three plans were used for the verifications: a static field of 10 x 10 cm² and two intensity modulated radiation therapy (IMRT) treatment plans. DSF were determined to be 1.13 for PMMA and 0.98 for PWDT. DSF for PMMA showed good agreement for AdC and CCC with 6 MV x ray, and AdC for 10 MV x ray. DSF for PWDT showed good agreement regardless of the dose calculation algorithms and x-ray energy. DSF can be considered one of the references for the density scaling factor of Delta4 phantom materials and may help improve the accuracy of the IMRT dose verification using Delta4.

PACS
87.55.km

KEY WORDS
Delta4, density scaling, dose verification, IMRT, phantom
1 | INTRODUCTION

It is necessary to verify the agreement between dose distributions calculated by a radiation treatment planning system (RTPS) and delivered by a linear accelerator (linac) for intensity modulated radiation therapy (IMRT).\(^1,2\) A number of approaches and systems have been developed for this verification.\(^2–13\) Recently, three-dimensional (3D) dose verification systems consisting of a solid phantom and detector arrays have become commercially available. These 3D dose verification systems can measure the absorbed dose at thousands of measurement points, and they are efficient in verifying the 3D dose distribution.

IMRT dose verifications should be evaluated more accurately. Kly et al.\(^14\) showed that institutional patient-specific IMRT quality assurance (QA) does not necessarily detect unacceptable plans. In their study, 14% of plans accepted by institutional IMRT QA were described as fail by an audit. In other words, even if an IMRT plan is accepted by one verification system, this does not ensure that the plan will be accepted by another verification system. Although various causes can be considered for this discrepancy, commissioning of verification systems is important to ensure the evaluation certainty. Because the verification is basically comparing the dose distributions in a solid phantom measured by the detectors and that calculated by the RTPS, the appropriate density scaling factor of the solid phantom used in the verification system should be adopted in the RTPS, where the density scaling factor is defined as a density to be assigned for the phantom material in RTPS (e.g., physical density, relative electron density, or other value).

A number of studies for IMRT 3D dose verification systems have been reported. One of these 3D dose verification systems (Delta4 (ScandiDos, Inc., Ashland, VA, USA)) consists of 1069 silicon diodes arranged on two orthogonal boards in polymethyl methacrylate (PMMA) or Plastic Water Diagnostic Therapy (PWDT) as shown in Fig. 1. It has been used for IMRT patient-specific QA,\(^13,15–20\) commissioning of volumetric modulated arc therapy (VMAT),\(^21\) and comparisons of dose calculation algorithms.\(^22,23\) However, these studies had an approximately 2% dose difference resulting from the difference in density scaling factors of the phantom materials. Pham et al.\(^15\) and Feygelman et al.\(^18\) evaluated Delta4 with the same photon energy, phantom material, and RTPS; the former adopted a density scaling factor of 1.19, while the latter adopted 1.14 for the PMMA phantom. Other studies\(^13,17,19,21–23\) have not reported the adopted density scaling factor, and their appropriateness has not been discussed so far.

The purpose of this study was to clarify the optimum density scaling factor for PMMA and PWDT in order to improve the accuracy of the calculated dose distributions in the phantom materials of Delta4. The density scaling factors proposed in this study (DSF) for PMMA and PWDT were determined from measurements and calculations with several algorithms. The appropriateness of the DSF was validated by dose verifications with several plans using commercially available algorithms.

![FIG. 1. Appearance of a 3D dose verification system (Delta4, ScandiDos). The silicon diodes are placed at 5 mm intervals in a central 6 cm × 6 cm area and at 10 mm intervals elsewhere in a 20 cm × 20 cm area on two orthogonal boards in the cylindrical phantom materials with a diameter of 22 cm. The standard detector geometry is depicted ("X"). If the attachment for sagittal-coronal option was used, the detector geometry could be rotated to the "+" orientation.](image-url)
For each phantom material, the appropriateness of DSF was verified through comparisons of the dose distributions measured with Delta4 and calculated with three different density scaling factors: the nominal physical density (PD), nominal relative electron density (ED), and DSF. The PDs of PMMA and PWDT are 1.190 and 1.039 g/cm³, and EDs of PMMA and PWDT are 1.159 and 1.003, respectively. The following dose calculation algorithms were used for the verification: AdC (Pinnacle³ ver. 9.0 for PMMA and 9.10 for PWDT), CCC, and AXB. Three plans were used for the verifications: one was mock head&neck and mock prostate in AAPM TG-119. The IMRT plans were created following the dose constraints shown in AAPM TG-119. The delivery techniques for the IMRT plans were step-and-shoot in Pinnacle³ and VMAT in the others. Before all measurements, the dose per monitor unit (DMU) of each x-ray energy was obtained in accordance with the standard dosimetry protocol, and the daily machine output was corrected by the daily correction factor from the built-in Delta4 software. These dose verifications were evaluated according to the pass rate of the global gamma index (gGI) for different criteria (2%/2 mm and 1%/1 mm) and the median of the global dose deviation (gDD) with the lower dose threshold of 20%. The normalization doses for the gGl and gDD were set to the measured dose at the isocenter for 10 × 10 and 2.0 Gy for the IMRT plans.
3 | RESULTS

3.A | $\mu_{\text{eff}}$ of TPRs

Figure 3 shows the measured $(\mu_{\text{eff}})_{\text{pl,water}}$ and changes in the calculated $(\mu_{\text{eff}})_{\text{pl,water}}$ for density scaling factors at a field size of $10 \times 10 \, \text{cm}^2$. The measured $(\mu_{\text{eff}})_{\text{pl,water}}$ were obtained within only the actual phantoms with no change in density, hence they are drawn as a horizontal line. The measured $(\mu_{\text{eff}})_{\text{pl,water}}$ at 6 and 10 MV were 1.13 and 1.13 for PMMA, and 0.98 and 0.98 for PWDT, respectively.

3.B | DSF of PMMA and PWDT

Based on Figs. 3 and 4, DSF$_{\text{regression}}$ was determined as the density scaling factor when the regression line matched the measured $(\mu_{\text{eff}})_{\text{pl,water}}$. At a field size of $10 \times 10 \, \text{cm}^2$, DSF$_{\text{regression}}$ of 6 and 10 MV X-ray were 1.13 and 1.14 for PMMA, and 0.98 and 0.99 for PWDT, respectively.
At a field size of 5 × 5 cm², DSF of Monte Carlo, AdC, CCC, and AXB for PMMA were 1.13, 1.13, 1.15, and 1.12 in 6 MV x ray, and 1.13, 1.13, 1.14, and 1.13 in 10 MV x ray, respectively. The $s_{DSF}$ of Monte Carlo, AdC, CCC, and AXB for PWDT were 0.97, 0.98, 0.98, and 0.97 in 6 MV x ray, and 0.98, 0.99, 0.98, and 0.98 in 10 MV x ray, respectively. At a field size of 10 × 10 cm², $s_{DSF}$ of Monte Carlo, AdC, CCC, and AXB for PMMA were 1.13, 1.13, 1.15, and 1.12 in 6 MV x ray, and 1.13, 1.13, 1.14, and 1.13 in 10 MV x ray, respectively. The $s_{DSF}$ of Monte Carlo, AdC, CCC, and AXB for PWDT were 0.97, 0.98, 0.99, and 0.98 in 6 MV x ray, and 0.99, 0.98, 0.99, and 0.98 in 10 MV x ray, respectively.

**Table 1.** Nominal physical density, nominal relative electron density, and DSF of PMMA and PWDT.

| Phantom material | Physical density [g cm⁻³] | Relative electron density | DSF |
|------------------|---------------------------|--------------------------|-----|
| PMMA             | 1.190                     | 1.159                    | 1.13|
| PWDT             | 1.039                     | 1.003                    | 0.98|

respectively. At a field size of 5 × 5 cm², $s_{DSF}$ of 6 and 10 MV x ray were 1.13 and 1.14 for PMMA, and 0.98 and 0.99 for PWDT, respectively. Therefore, DSF in this study was determined as 1.13 for PMMA and 0.98 for PWDT, as given in Table 1.

**Fig. 4.** Calculated $(\mu_{\text{eff}})_{\text{pl,water}}$ as a function of density scaling factor for dose calculation and measured $(\mu_{\text{eff}})_{\text{pl,water}}$ represented as a horizontal line (field size = 5 × 5 cm²). The regression line approximating the median values of the calculated $(\mu_{\text{eff}})_{\text{pl,water}}$ of the dose calculation algorithms at each density scaling factor is represented as a diagonal dashed line.
3.C | Dose verifications with different density scaling factors

Figure 5 shows the measured and calculated dose profiles in Delta4 PMMA phantom with AdC for the several dose verifications using PD and DSF. These verification plans were 10 × 10 with 6 MV x ray, mock head&neck with 6 MV x ray, and mock prostate with 10 MV x ray. Fig. 6 shows the pass rates of gGI and median of gDD of the dose calculation algorithms with different density scaling factors for the dose verifications of 10 × 10 with 6 MV x ray. Tables 2 and 3 show the summary of the pass rates of gGI and median of gDD of the dose calculation algorithms with different density scaling factors for the dose verifications of 10 × 10 and IMRT within PMMA and PWDT.

Figure 6 shows the graphs of the numerical data of 10 × 10 with 6 MV x ray in Tables 2 and 3. The pass rates of gGI and median of

---

**Fig. 5.** Comparisons between the measured and calculated dose profiles in the Delta4 PMMA phantom with AdC for the several dose verifications using PD and DSF. The pictures at the upper left show the measured dose distributions for each plan on one of the two orthogonal detector boards and the blue lines on the pictures show the position of the displayed profiles. [Correction added on 28 May, after first Online publication: Figure 5 position rearrangement has been updated.]
gDD were changed dramatically according to the changes of adopted density scaling factors. For AdC (ver.9.0) in PMMA, there was an unreasonable change at the ED. The measured dose distributions were consistent regardless of the adopted density scaling factors in the dose verifications. The calculated dose distributions should change according to the adopted density scaling factor; the calculated
dose should become gradually higher when the adopted density scaling factor becomes gradually lower. However, the median of gDD using ED (1.159) was not between that using PD (1.19) and DSF (1.13). This may be due to the coarse resolution of the mass attenuation coefficient in an older version of Pinnacle3, as pointed out by Dickof.31 Except for AXB within PMMA, the pass rates of gGI increased and median of gDD moved close to 0% from the PD to DSF. The tendency was consistent regardless of the dose calculation algorithms, verification plans, and x-ray energy within PWDT, as shown in Table 3. DSF for PWDT showed good agreement between the measured and calculated dose distributions under multiple conditions. On the other hand, as shown in Table 2, DSF for PMMA showed good agreement between those in AdC and CCC with 6 MV x ray, and AdC for 10 MV x ray for 10 × 10. The PD or ED showed good agreement between those in AXB with 6 MV x ray, and CCC and AXB with 10 MV x ray for 10 × 10. The results within PMMA varied depending on the dose calculation algorithms and x-ray energy. Although the dose verifications of 10 × 10 for AXB within PMMA were conducted in three institutions after the absolute dose calibration for the Delta4 detectors, these results were unchanged. This removes the dependence of these results on site-specific errors such as linac output, cross-calibration of Delta4, or beam data in RTPS.

In Tables 2 and 3, the results for CCC within PMMA and PWDT were obtained at one institution, and those for AXB within PMMA and PWDT were obtained at a different institution. Although the results of the dose verifications for CCC within PWDT were consistent for both 6 and 10 MV x ray, the results for CCC within PMMA were not consistent. The optimum density scaling factor for CCC in PMMA was DSF in 6 MV x ray and ED in 10 MV x ray. Although the results of mock head&neck for CCC with 10 MV x ray were slightly different from those of 10 × 10 and mock prostate in PMMA, it was the same tendency as that seen in the results in PWDT. However, the optimum density scaling factor of PMMA for AXB seemed to be PD or ED in 10 × 10 and DSF in IMRT. The reason may be the systematic dose difference of 1% for the IMRT plans between the linac output and dose calculation in the institution. The results of the IMRT verifications in PWDT were also higher by 1% compared to 10 × 10.

4 | DISCUSSION

The choice of density scaling factor has a large effect on the ability to accurately calculate dose distributions in the Delta4 phantoms.
This is evidenced by the fact that the average difference of the pass rates of gGI with the criterion of 2%/2 mm between PD and DSF for mock head&neck plans in 6 MV x ray were 25.8% in PMMA and 25.2% in PWDT. Furthermore, as shown in Fig. 5, the calculated dose profiles adopted with PD were clearly different from both the measured dose distributions and the calculated dose profiles adopted with DSF. The choice of density scaling factor plays a crucial role not only for patient-specific IMRT QA in order to appropriately judge for pass or fail, but also for the IMRT commissioning for RTPS. The reason why the choice is important for the IMRT commissioning is that the calculated dose distributions would need to be adjusted by modifying several dose calculation parameters (e.g., dosimetric leaf gap, MLC transmission, tongue and groove effect, or focal spot size) compared with measured dose distributions.

Although the relative electron density is commonly assigned to solid phantoms in RTPS, its appropriateness for density scaling has been demonstrated for the equivalent path length in narrow photon beams. However, the optimum density scaling factor for 3D dose verification is not the ratio for the equivalent path length of photon interactions but the density in RTPS that gives a calculated dose distribution closely matching the measured dose distribution. Therefore, the DSFs were obtained according to the changes of depth dose that included the component of the scattered dose in the phantoms. To determine the cause for this divergence as the component of the scattered dose in the phantom or others, further study should be conducted with more types of solid phantoms and geometry conditions. In this study for the density scaling factors of Delta4 phantom materials, DSFs were obtained as lower values than the nominal relative electron densities through our original method.

Regarding the density scaling factors of PMMA applied in other studies of Delta4, Pham and Luo used 1.19 in Pinnacle. Geurts et al. used 1.19 in TomoTherapy system. Kumagai et al. found 1.16 for 4 MV and 1.15 for 10 MV in Pinnacle. Feygelman et al. used 1.14 in Pinnacle and their value was close to the DSF in the previous studies. TG-21 was the reference for the relative electron density.

### Table 3
Summary of the pass rates (%) of gGI with the criteria of 2%/2 mm and 1%/1 mm, and median (%) of gDD of several dose calculation algorithms with physical density (PD), relative electron density (ED), and DSF for PWDT.

| Plan/x-ray energy Metrics | AdC | CCC | AXB |
|---------------------------|-----|-----|-----|
|                          | PD  | ED  | DSF | PD  | ED  | DSF |
| 10 × 10/6 MV              |     |     |     |     |     |     |
| gGI (2%/2 mm)             | 57.3| 100.0| 100.0| 39.1| 96.0| 100.0| 82.7| 99.8| 98.9|
| gGI (1%/1 mm)             | 23.1| 71.7| 96.3| 20.7| 37.2| 81.4| 36.4| 74.4| 82.1|
| Median of gDD             | 2.1 | 0.8 | 0.2 | 2.5 | 1.4 | 0.6 | 1.5 | 0.4 | −0.3|
| Mock head&neck/6 MV       |     |     |     |     |     |     |
| gGI (2%/2 mm)             | 74.7| 90.1| 96.0| 73.4| 92.8| 98.8| 62.4| 78.7| 91.4|
| gGI (1%/1 mm)             | 53.4| 63.8| 69.8| 52.7| 70.0| 81.8| 42.7| 54.5| 68.2|
| Median of gDD             | 1.4 | 0.6 | 0.1 | 1.9 | 0.9 | 0.2 | 1.9 | 1.3 | 0.7|
| 10 × 10/10 MV             |     |     |     |     |     |     |
| gGI (2%/2 mm)             | 99.0| 100.0| 100.0| 96.9| 100.0| 100.0| 84.0| 99.8| 100.0|
| gGI (1%/1 mm)             | 43.2| 96.9| 95.2| 46.6| 93.7| 97.1| 36.0| 69.3| 87.1|
| Median of gDD             | 1.4 | 0.4 | −0.1| 1.3 | 0.5 | 0.0 | 1.4 | 0.7 | 0.2|
| Mock head&neck/10 MV      |     |     |     |     |     |     |
| gGI (2%/2 mm)             | 90.3| 99.4| 100.0| 84.7| 95.2| 98.5| 63.8| 78.3| 87.3|
| gGI (1%/1 mm)             | 62.5| 78.3| 83.2| 56.9| 75.9| 85.8| 37.6| 48.2| 60.3|
| Median of gDD             | 1.1 | 0.3 | 0.1 | 1.7 | 1.0 | 0.6 | 2.2 | 1.5 | 1.1|
| Mock prostate/10 MV       |     |     |     |     |     |     |
| gGI (2%/2 mm)             | 90.3| 99.4| 100.0| 94.9| 99.7| 100.0| 76.6| 90.5| 96.6|
| gGI (1%/1 mm)             | 62.5| 78.3| 83.7| 80.0| 93.6| 93.9| 53.2| 67.8| 78.4|
| Median of gDD             | 1.1 | 0.3 | 0.1 | 1.1 | 0.3 | −0.1| 1.9 | 1.3 | 1.0|
density of 1.14. TG-21 calculated a relative electron density of 1.137 from the physical density of 1.17 g/cm³ for PMMA. However, the physical density of PMMA was shown as 1.19 g/cm³. In additional investigations, we measured the physical density and analyzed the elemental composition of PMMA in a portion of Delta4 with the thermal conductivity method for hydrogen and carbon, and the infrared absorption spectrophotometry for oxygen. Consequently, the physical density was 1.19 g/cm³, and the elemental composition closely matched the nominal elemental composition. The DSF are the lowest density scaling factor acquired theoretically.

DSF was shown to be the optimum density scaling factor for PWDT regardless of the dose calculation algorithm and x-ray energy. Furthermore, the changes of the \( \rho_{\text{eff}} \) calculated by the dose calculation algorithms were consistent at each density scaling factor for PWDT. On the other hand, these changes were not consistent for PMMA. Specifically, these changes of AdC were lower than those of other dose calculation algorithms and those of AXB were higher in several conditions, as shown in Figs. 3 and 4. The reason these differences occurred in treating different densities of water in the calculations opened to the public were limited. At least, the results showed the possibility that optimum density scaling factor for AdC may become higher than DSF such as ED and the one for AXB may become lower than DSF through the dose verifications. However, in the dose verifications for PMMA, DSF was the optimum density scaling factor in AdC and CCC with 6 MV x-ray, and AdC with 10 MV x-ray. The PD or ED may be the optimum density scaling factor in AXB with 6 MV x-ray, and CCC and AXB with 10 MV x-ray, nevertheless none of the \( \rho_{\text{eff}} \) calculated by the dose calculation algorithms matched the measured \( \rho_{\text{eff}} \) at PD and ED, as shown in Fig. 2. A reason for the considerable deviation may be the accuracy of the absorbed dose calculation in a higher density of water. Because DSF were obtained from the slopes of the TPRs, the DSF were not found to be an appropriate density scaling factor for the absorbed dose calculation in different densities of water. If there was some mismatch or uncertainty between the slope of the depth dose and absorbed dose calculated in a different density of water, it should be corrected by something other than the density scaling factor.

5 | CONCLUSIONS

The difference in density scaling factors caused a bigger dosimetric difference than the pass/fail criterion. We clarified DSF of PMMA and PWDT from measurements and calculations, and validated the appropriateness of DSF. The DSF were lower than not only the PD but also the ED. DSF can be used as a reference for the density scaling factor of the Delta4 phantom material in multiple clinical institutions and may help improve the accuracy of the IMRT dose verification using Delta4.

ACKNOWLEDGMENTS

The authors would like to thank Satoshi Kito from Tokyo Metropolitan Komagome Hospital, and Hiroyuki Okamoto and Satoshi Nakamura from National Cancer Center Hospital for their help on the early stages of this study.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Ezzel GA, Galvin JM, Low D, et al. Guidance document on delivery, treatment planning, and clinical implementation of IMRT: Report of the IMRT subcommittee of the AAPM radiation therapy committee. Med Phys. 2003;30:2089–2115.
2. Low DA, Moran JM, Dempsey JF, Dong L, Oldham M. Dosimetry tools and techniques for IMRT. Med Phys. 2011;38:1313–1338.
3. Kruse JJ. On the insensitivity of single planar dosimetry to IMRT inaccuracies. Med Phys. 2010;37:2516–2524.
4. de Wagara C. The ideal dosimeter for intensity modulated radiation therapy (IMRT): what is required? J Phys Conf Ser. 2004;3:4–8.
5. Schreibmann E, Dhabaan A, Elder E, Fox T. Patient-specific quality assurance method for VMAT treatment delivery. Med Phys. 2009;36:4530–4535.
6. van Elmpt W, Nijsten S, Mijnheer B, Dekker A, Lambin P. The next step in patient-specific QA: 3D dose verification of conformal and intensity-modulated RT based EPID dosimetry and Monte Carlo dose calculations. Radiother Oncol. 2008;86:86–92.
7. Siochi RA, Molineu A, Orton CG. Point/Counterpoint: patient-specific QA for IMRT should be performed using software rather than hardware methods. Med Phys. 2013;40:070601.
8. Hussein M, Rowshanfarzad P, Ebert MA, Nisbet A, Clark CH. A comparison of the gamma index analysis in various commercial IMRT/VMAT QA systems. Radiat Oncol. 2013;109:370–376.
9. Nelms BE, Zhen H, Tome WA. Per-beam, planar IMRT QA passing rates do not predict clinically relevant patient dose errors. Med Phys. 2011;38:1037–1044.
10. Jursinic PA, Sharma R, Reuter J. MapCHECK used for rotational IMRT measurements: step-and-shoot, Tomotherapy. RapidArc Med Phys. 2010;37:2837–2846.
11. Statathakis S, Myers P, Esquivel C, Mavrodis P, Papanikolaou N. Characterization of a novel 2D array dosimeter for patient-specific quality assurance with volumetric arc therapy. Med Phys. 2013;40:071731.
12. Neilson C, Klein M, Barnett R, Yartsev S. Delivery quality assurance with volumetric arc therapy. Med Phys. 2011;38:1037–1044.
13. Sadagopan R, Bencombe JA, Martin RL, Nilsson G, Matzen T, Balter PA. Characterization and clinical evaluation of a novel IMRT quality assurance system. J Appl Clin Med Phys. 2009;10:104–119.
14. Kly SF, Molineu A, Kerns JR, et al. Institutional patient-specific IMRT QA does not predict unacceptable plan delivery. Int J Radiat Oncol Biol Phys. 2014;90:1195–1201.
15. Pham T, Luo J. Clinical implementation of a 3D dosimeter for accurate IMRT and VMAT patient specific QA. Open J Biophys. 2013;3:99–111.
16. Fegyelmand V, Opp D, Javedan K, Saini AJ, Zhang G. Evaluation of a 3D diode array dosimeter for helical Tomotherapy delivery QA. Med Dosim. 2010;35:324–329.
17. Fegyelmand V, Zhang G, Stevens C, Nelms BE. Evaluation of a new VMAT QA device, or the “X” and “O” array geometries. J Appl Clin Med Phys. 2011;12:146–168.
18. Feygelman V, Forster K, Opp D, Nilsson G. Evaluation of a biplanar diode array dosimeter for quality assurance of step-and-shoot IMRT. J Appl Clin Med Phys. 2009;10:64–78.

19. Bedford JL, Lee YK, Wai P, South CP, Warrington AP. Evaluation of the Delta4 phantom for IMRT and VMAT verification. Phys Med Biol. 2009;54:167–176.

20. Geurts M, Gonzalez J, Ojeda PS. Longitudinal study using a diode phantom for helical tomotherapy IMRT QA. Med Phys. 2009;36:4977–4983.

21. Bedford JL, Warrington AP. Commissioning of volumetric modulated arc therapy (VMAT). Int J Radiat Oncol Biol Phys. 2009;73:537–545.

22. Fotina I, Kragl G, Kroupa B, Trausmuth R, Georg D. Clinical comparison of dose calculation using the enhanced collapsed cone algorithm vs. a new Monte Carlo algorithm. Strahlenther Onkol. 2011;187:433–441.

23. Kragl G, Albrich D, Georg D. Radiation therapy with unflattened photon beams: dosimetric accuracy of advanced dose calculation algorithms. Radiother Oncol. 2011;100:417–423.

24. Kawarikow I, Rogers DWO. The EGSnrc code system: Monte Carlo simulation of electron and photon transport. National Research Council of Canada Report No. PIRS-701. 2006.

25. Wulff J, Heverhagen JT, Zink K. Monte-Carlo-based perturbation and beam quality correction factors for thimble ionization chambers in high-energy photon beams. Phys Med Biol. 2008;53:2823–2836.

26. Rogers DWO, Faddegon BA, Ding GX, Ma CM, We J, Mackie TR. BEAM: Monte Carlo code to simulate radiotherapy treatment units. Med Phys. 1995;22:503–524.

27. Hirayama H, Namito Y, Bielajew AF, Wilderman SJ, Nelson WR. The EGS5 code system. Stanford Linear Accelerator Center Report No. 730/KEK Report No. 2005-8.

28. Japanese Society of Medical Physics. Standard dosimetry of absorbed dose to water in external beam radiotherapy (Standard Dosimetry 12). Tsusho Sagyo Kenkyu Sha. 2012. (in Japanese)

29. Araki F, Hanyu Y, Fukuoka M, Matsumoto K, Okumura M, Oguchi H. Monte Carlo calculations of correction factors for plastic phantoms in clinical photon and electron beam dosimetry. Med Phys. 2009;36:2992–3001.

30. Ezzell GA, Burmeister JW, Dogan N, et al. IMRT commissioning: multiple institution planning and dosimetry comparisons, a report from AAPM Task Group 119. Med Phys. 2009;36:5359–5373.

31. Dickof P. Density scaling artifacts in dosimetry calculations. J Appl Clin Med Phys. 2005;6:118–121.

32. Yao W, Farr JB. Determining the optimal dosimetric leaf gap setting for rounded leaf-end multileaf collimator system by simple test fields. J Appl Clin Med Phys. 2015;16:65–77.

33. Glide-Hurst C, Bellon M, Foster R, et al. Commissioning of the Varian TrueBeam linear accelerator: a multi-institutional study. Med Phys. 2013;40:031719-1–031719-15.

34. Chen S, Yi BY, Yang X, Xu H, Prado KL, D’Souza WD. Optimizing the MLC model parameters for IMRT in the RayStation treatment planning system. J Appl Clin Med Phys. 2015;16:322–332.

35. Gardner SJ, Lu S, Liu C, Wen N, Chetty U. Tuning of AcurosXB source size setting for small intracranial targets. J Appl Clin Med Phys. 2017;18:170–181.

36. Seco J, Evans PM. Assessing the effect of electron density in photon dose calculations. Med Phys. 2006;33:540–552.

37. Kumagai S, Okajima M, Takaya H, et al. The improvement of discrepancy between radiotherapy treatment planning system and verification system using effective density method. KEK Proc. 2012;7:66–75.

38. Task Group No. 21, Radiation Therapy Committee, AAPM. A protocol for the determination of absorbed dose from high-energy photon and electron beams. Med Phys. 1983;10:741–771.

39. IAEA, Absorbed dose determination in external radiotherapy: An international code of practice for dosimetry based on standards of absorbed dose to water. TRS-398. Vienna: International Atomic Energy Agency; 2004.